Literature DB >> 28795231

Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.

Tsunehito Nakao1, Yasuo Sasagawa2, Sumihito Nobusawa3, Yasushi Takabatake4, Hemragul Sabit1, Masashi Kinoshita1, Katsuyoshi Miyashita1, Yasuhiko Hayashi1, Hideaki Yokoo3, Mitsutoshi Nakada1.   

Abstract

Radiation-induced glioma (RIG) is a rare secondary glioma. The tumors morphologically resemble their sporadically arising counterparts. Recently, the WHO classification of tumors of the central nervous system was revised to incorporate molecular biomarkers together with classic histological features. The status of molecular biomarkers in RIG, however, remains unclear. The objective of this study was to investigate if commonly accepted glioma-specific biomarkers are relevant in RIGs. Among 269 gliomas diagnosed as WHO grade 2, 3 and 4 in our institution, four were diagnosed as RIGs. Immunohistochemical (IHC) staining for isocitrate dehydrogenase 1 (IDH1), p53, alpha thalassemia/mental retardation syndrome X-linked (ATRX), and H3K27M, and direct DNA sequencing of IDH1/2, telomerase reverse transcriptase (TERT) promoter, Histone H3.3 (H3F3A) and B-Raf (BRAF) genes was performed. All tumor specimens were IDH1-, p53- and H3K27M-negative. The nuclei of tumor cells in all cases exhibited positive staining for ATRX. In direct DNA sequencing analysis, no IDH1, IDH2, TERT promoter, H3F3A or BRAF mutations were found in any of the cases. Our findings suggest that these characteristic glioma-associated molecular mutations may be rare events in RIGs. More RIGs need to be tested for analysis of molecular biomarkers to clarify the clinical and histopathological spectra of this tumor.

Entities:  

Keywords:  Gene mutation; Molecular marker; Radiation therapy; Radiation-induced glioma

Mesh:

Substances:

Year:  2017        PMID: 28795231     DOI: 10.1007/s10014-017-0292-x

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  4 in total

1.  Secondary brain tumors after cranial radiation therapy: A single-institution study.

Authors:  Masazumi Fujii; Masahiro Ichikawa; Kensho Iwatate; Mudathir Bakhit; Masayuki Yamada; Yosuke Kuromi; Taku Sato; Jun Sakuma; Hisashi Sato; Atsushi Kikuta; Yoshiyuki Suzuki; Kiyoshi Saito
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-30

2.  The genetic landscape of gliomas arising after therapeutic radiation.

Authors:  Giselle Y López; Jessica Van Ziffle; Courtney Onodera; James P Grenert; Iwei Yeh; Boris C Bastian; Jennifer Clarke; Nancy Ann Oberheim Bush; Jennie Taylor; Susan Chang; Nicholas Butowski; Anuradha Banerjee; Sabine Mueller; Cassie Kline; Joseph Torkildson; David Samuel; Aleli Siongco; Corey Raffel; Nalin Gupta; Sandeep Kunwar; Praveen Mummaneni; Manish Aghi; Philip Theodosopoulos; Mitchel Berger; Joanna J Phillips; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2018-09-08       Impact factor: 15.887

Review 3.  Defining the molecular features of radiation-induced glioma: A systematic review and meta-analysis.

Authors:  Jacqueline P Whitehouse; Meegan Howlett; Aniello Federico; Marcel Kool; Raelene Endersby; Nicholas G Gottardo
Journal:  Neurooncol Adv       Date:  2021-08-12

4.  Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.

Authors:  Makoto Ohno; Yasuji Miyakita; Masamichi Takahashi; Shunsuke Yanagisawa; Yukie Tamura; Daisuke Kawauchi; Miyu Kikuchi; Hiroshi Igaki; Akihiko Yoshida; Kaishi Satomi; Yuko Matsushita; Koichi Ichimura; Yoshitaka Narita
Journal:  Radiat Oncol       Date:  2022-05-03       Impact factor: 4.309

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.